全球糖尿病视网膜病变市场 – 行业趋势及 2029 年预测

全球糖尿病视网膜病变市场分析和规模

近年来，糖尿病视网膜病变市场预计在预测期内将快速增长。糖尿病视网膜病变 (DR) 是全球视力丧失的最常见原因。高血糖、糖尿病和高血压的持续时间是视力丧失进展最重要的临床风险因素。控制血糖和血压已被证明有助于预防因糖尿病视网膜病变导致的视力丧失。根据国际糖尿病联合会 (IDF) 的数据，2015 年至 2019 年，全球糖尿病 (DM) 的患病率约为 27%。患病率最低的是欧洲 (20.6%) 和东南亚 (12.5%)，患病率最高的是非洲 (33.8%)、中东和北非 (33.8%) 和西太平洋地区 (36.2%)。

• Data Bridge Market Research 分析称，2021 年糖尿病视网膜病变市场价值为 66 亿美元，预计到 2029 年将达到 126.8 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 8.50%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

全球糖尿病视网膜病变市场定义

糖尿病会损害视网膜中的血管，导致糖尿病视网膜病变 (DR)。糖尿病视网膜病变有两种类型：非增生性糖尿病视网膜病变和增生性或进展性糖尿病视网膜病变。糖尿病视网膜病变是由血糖水平的变化引起的，导致眼睛中的感光结构异常生长。视野中出现黑斑或浮线、视力模糊或波动、色觉下降或视力丧失都是糖尿病视网膜病变的症状。

报告范围和市场细分

Diabetic Retinopathy Market Dynamics

Drivers

• Increasing prevalence of diabetes

The rising prevalence of diabetes is a primary driver of the diabetic retinopathy market's growth. Along with this, the rising cases of blindness due to diabetes will further influence the market dynamics during the forecast period.   

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of diabetic retinopathy market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the diabetic retinopathy market. Additionally, high disposable income and favourable reimbursement scenario will result in the expansion of diabetic retinopathy market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the diabetic retinopathy market growth. Along with this, rising approvals and launches of new diabetic retinopathy drugs will further propel the 'market's growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the diabetic retinopathy market growth during the forecast period.

Restraints/Challenges Global Diabetic Retinopathy Market

On the other hand, the high cost associated with the treatment of diabetic retinopathy will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the diabetic retinopathy market. Additionally, a decline in clinical visits due to COVID-19 outbreak and post-surgical complications will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This diabetic retinopathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the diabetic retinopathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Diabetic retinopathy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Diabetic Retinopathy Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery, while prioritizing COVID-19-related treatments, healthcare systems worldwide have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of diabetic retinopathy in recent months.

Recent Development

• In August 2020, Eyenuk had announced the U.S. Food and Drug Administration (FDA) approval for EyeArt Autonomous AI System for diabetic retinopathy screening. EyeArt is designed to help healthcare providers detect more than moderate diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR) in the eyes of adults with diabetes who have never been diagnosed with more than mild diabetic retinopathy.

Global Diabetic Retinopathy Market Scope

The diabetic retinopathy market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Non-Proliferative Diabetic Retinopathy
• Proliferative Diabetic Retinopathy

Type segment for the diabetic retinopathy market is categorized into non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.

Treatment

• Medication
• Device
• Surgery
• Others

Based on treatment, the diabetic retinopathy market is segmented into medication, device, surgery and others. The medication section is further categorized into anti-vascular endothelial growth factor drug, intravitreal steroid, lipid lowering drugs and others. The device section has been sub-segmented into focal laser, vitrectomy devices, scatter laser and others.

Diagnosis

• Fluorescein Angiography
• Optical Coherence Tomography
• Others

Based on diagnosis, the diabetic retinopathy market is segmented into fluorescein angiography, optical coherence tomography and others.

Route of Administration

• Oral
• Intravitreal Injections
• Intravitreal Implants
• Others

The route of administration segment for global diabetic retinopathy market is segmented into oral, intravitreal injections, intravitreal implants and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the diabetic retinopathy market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

根据分销渠道，糖尿病视网膜病变市场也细分为医院药房、零售药房、网上药房和其他。

糖尿病视网膜病变市场区域分析/见解

对糖尿病视网膜病变市场进行了分析，并按国家、类型、治疗、诊断、给药途径、最终用户和分销渠道提供了市场规模见解和趋势，如上所述。

糖尿病视网膜病变市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区

北美在糖尿病视网膜病变市场占据主导地位，因为该地区糖尿病视网膜病变的患病率不断上升，且医疗费用不断增加。此外，主要关键参与者对新技术的关注度不断提高，这将进一步推动该地区市场的增长速度。

由于亚太地区人口和医疗保健支出的不断增加，预计 2022 年至 2029 年预测期内亚太地区将实现增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和糖尿病视网膜病变市场份额分析

糖尿病视网膜病变市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对糖尿病视网膜病变市场的关注有关。

糖尿病视网膜病变市场的一些主要参与者包括：

• LEO Pharma A/S（丹麦）
• Amneal Pharmaceuticals LLC.（美国）
• Glenmark 制药有限公司（印度）
• Dr.'Reddy's Laboratories Ltd.（印度）
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• Bausch Health Companies Inc.（加拿大）
• 礼来公司 (美国)
• AbbVie Inc.（美国）
• 雅培（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 诺华公司（瑞士）
• 太阳制药工业有限公司 (印度)
• Aurobindo Pharma（印度）
• 鲁冰花（印度）
• 艾尔建（爱尔兰）
• 默克公司（美国）
• IRIDEX 公司 (美国)
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)

SKU-53232